
Formulation of Liposomes and Niosomes for Targeted Therapy

Dr. Meenal Sharma

Associate Professor

Department of Pharmaceutics

Sunrise Institute of Pharmaceutical Sciences, Jaipur, India

Email Id: meenalsharma.research@rocketmail.com

Mr. Karan Malhotra

Research Scholar

School of Pharmaceutical Technology

Green Valley University, Pune, India

Email Id: karanmalhotra_academic@yahoo.co.in

ABSTRACT

Liposomes and niosomes are widely researched vesicular systems in modern pharmaceutics due to their potential in improving drug targeting, enhancing therapeutic efficacy, and reducing systemic side effects. These nanocarriers can encapsulate both hydrophilic and hydrophobic drugs, making them versatile tools in treating chronic diseases, cancer, and infections. Liposomes are phospholipid-based vesicles, while niosomes are formed using non-ionic surfactants, each offering unique advantages in formulation, stability, and cost-effectiveness. This paper provides a comprehensive discussion on the formulation strategies, preparation methods, characterization techniques, therapeutic applications, comparative analysis, challenges, and future perspectives of liposomes and niosomes in targeted therapy.

Keywords: Liposomes, Niosomes, Targeted Therapy, Nanocarriers, Drug Delivery Systems, Formulation

INTRODUCTION

Drug delivery systems have advanced significantly in recent decades, moving beyond conventional dosage forms toward targeted therapeutic carriers. Among the most important

nanocarriers, liposomes and niosomes stand out for their ability to enhance drug bioavailability, minimize adverse effects, and enable site-specific delivery. Traditional oral and parenteral formulations often fail to reach the desired therapeutic index due to rapid metabolism, degradation, or systemic toxicity. Vesicular carriers provide an innovative solution by offering controlled release and targeted delivery of drugs.

Liposomes were first discovered in the 1960s by Alec Bangham as phospholipid bilayer vesicles capable of mimicking cellular membranes. Since then, they have been developed for numerous clinical applications. Niosomes, introduced later in the 1970s and 80s, utilize non-ionic surfactants instead of phospholipids, providing greater stability and cost-effectiveness. Both systems are now crucial in cancer therapy, vaccine delivery, and treatment of infectious diseases.

FORMULATION ASPECTS

Formulation of vesicular systems involves selecting appropriate materials and stabilizers.

- **Liposomes:** Primarily composed of phospholipids and cholesterol, forming bilayer structures. Drugs are encapsulated either in the aqueous core (hydrophilic) or within the lipid bilayer (hydrophobic). Stabilizers, antioxidants, and cryoprotectants are often added to prevent degradation.
- **Niosomes:** Prepared using non-ionic surfactants such as Span, Tween, or Brij, along with cholesterol to improve membrane rigidity. They are more chemically stable compared to liposomes and less expensive, making them attractive for large-scale production.

The ratio of lipid to cholesterol, surfactant concentration, and hydration medium significantly influence vesicle size, entrapment efficiency, and release profile.

METHODS OF PREPARATION

Different preparation techniques have been employed to produce liposomes and niosomes of controlled size and morphology.

1. **Thin Film Hydration Method:** Phospholipids or surfactants dissolved in organic solvent are evaporated to form a thin film, followed by hydration with aqueous drug solution.
2. **Reverse Phase Evaporation:** Useful for encapsulating hydrophilic drugs with higher efficiency.

3. **Microfluidization:** Employs high-pressure homogenization for uniform nanosized vesicles.
4. **Ethanol Injection and Ether Injection:** Simplified techniques where organic solutions are injected into aqueous phase.
5. **Sonication and Extrusion:** Used to reduce vesicle size and produce unilamellar vesicles.

Each method offers advantages depending on drug solubility, desired vesicle size, and stability requirements.

CHARACTERIZATION PARAMETERS

Thorough evaluation is essential to ensure reproducibility, stability, and therapeutic efficacy of vesicles.

- **Vesicle size and polydispersity index (PDI):** Determined using dynamic light scattering.
- **Entrapment efficiency:** Measured as the percentage of drug successfully encapsulated.
- **Zeta potential:** Indicates surface charge and predicts stability.
- **Morphology:** Visualized using transmission electron microscopy (TEM) or scanning electron microscopy (SEM).
- **In vitro drug release studies:** Conducted to determine controlled or sustained release behavior.
- **Stability studies:** Performed under different storage conditions to check physical and chemical integrity.

THERAPEUTIC APPLICATIONS

Liposomes and niosomes have been widely investigated for their use in targeted therapy.

- **Cancer Therapy:** Liposomal formulations such as Doxil® (doxorubicin liposomes) are FDA-approved for cancer treatment, offering reduced cardiotoxicity compared to free drug. Niosomes encapsulating paclitaxel and methotrexate have shown promising antitumor activity.
- **Infectious Diseases:** Liposomal amphotericin B is widely used for fungal infections, providing reduced nephrotoxicity. Niosomes have been explored for antibacterial and antiviral drug delivery.
- **Vaccine Delivery:** Vesicular systems enhance antigen stability and immune response. Liposomal vaccines for influenza and hepatitis are in advanced trials.

- **Neurological Disorders:** Liposomes and niosomes are being developed for crossing the blood–brain barrier for diseases like Alzheimer’s and Parkinson’s.
- **Topical and Transdermal Delivery:** Niosomal gels and liposomal creams enhance drug permeation for dermatological conditions.

COMPARATIVE ADVANTAGES

Table 1: Comparative analysis of liposomes and niosomes in drug delivery

Parameter	Liposomes	Niosomes
Basic Composition	Phospholipids, cholesterol	Non-ionic surfactants, cholesterol
Stability	Prone to oxidation, hydrolysis	Higher stability against chemical degradation
Cost	Relatively expensive	Cost-effective and economical
Biocompatibility	Highly biocompatible and biodegradable	Good, but may depend on surfactant type
Regulatory acceptance	Widely approved in pharmaceutical use	Still under research in many therapeutic areas

CHALLENGES AND FUTURE PERSPECTIVES

Despite their potential, several challenges hinder the widespread adoption of liposomes and niosomes.

- **Scalability and Manufacturing:** Large-scale production requires advanced equipment and strict quality control.
- **Stability:** Liposomes suffer from oxidative degradation, while niosomes may exhibit leakage under stress conditions.
- **Cost and Raw Materials:** Liposomal formulations are expensive, while niosomal systems may face regulatory limitations.
- **Targeting Specificity:** Active targeting requires functionalization with ligands, antibodies, or peptides.

Future Directions:

- Development of stimuli-responsive vesicles (pH, temperature, magnetic field) for smart delivery.
- Integration with nanotechnology and bioengineering to produce hybrid systems with superior properties.
- Improved regulatory frameworks and large-scale trials for clinical acceptance.

CONCLUSION

Liposomes and niosomes represent vital advancements in targeted therapy, offering significant improvements in drug encapsulation, delivery, and controlled release. While liposomes are better established clinically, niosomes offer economical and stable alternatives. The future lies in combining their unique advantages with novel biomaterials, targeted ligands, and advanced preparation techniques. These vesicular systems hold great promise in oncology, infectious disease treatment, vaccination, and transdermal therapy. With ongoing research and technological progress, liposomes and niosomes are set to play a crucial role in next-generation nanomedicine.

REFERENCES

1. Sahoo, S.K., Labhasetwar, V. Nanotech approaches to drug delivery and imaging. *Drug Discovery Today*, 8(24), 2003.
2. Mozafari, M.R. Liposomes: an overview of manufacturing techniques. *Cellular & Molecular Biology Letters*, 10, 2005.
3. Lasic, D.D. *Liposomes: From Physics to Applications*. Elsevier, 1993.
4. Uchegbu, I.F., Vyas, S.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery. *International Journal of Pharmaceutics*, 172, 1998.
5. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. *Nature Reviews Drug Discovery*, 4, 2005.
6. Kumar, G.P., Rajeshwarrao, P. Nonionic surfactant vesicular systems for effective drug delivery. *Journal of Pharmaceutical Sciences*, 100(7), 2011.
7. Allen, T.M., Cullis, P.R. Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65, 2013.
8. Bangham, A.D. Surrogate cells or Trojan horses. The discovery of liposomes. *Bioessays*, 14(9), 1992.

